#us-health-policy

#us-health-policy

The joint statement from Rubio and Kennedy, a vaccine sceptic, primarily blamed the WHO's failures during the COVID-19 pandemic as the reason for the withdrawal. Going forward, US engagement with the WHO will be limited strictly to effectuate our withdrawal and to safeguard the health and safety of the American people, Rubio and Kennedy said, noting that all US funding for the WHO had ceased.

We're living in a curious moment for the status of cancer diagnosis and treatment, within the United States. The overall rate of prevalence for diseases that fall under the wide, wide title of "cancers" is increasing. At the same time, steady improvement to the standard of care and treatment, and newer breakthroughs in therapeutics, have raised survival rates higher than they've ever been before. But for all too many patients, the question is whether they'll be able to afford those

Health insurance has once again become a battleground in US politics. With costs rising and government subsidies under pressure, Republicans and Democrats remain sharply divided over how much the government should pay for health insurance and how much should be left to market forces. Supporters of public investment say broader coverage strengthens the economy and protects families. Critics say it drives up costs and weakens competition.

Donald Trump, always one to tout his knack for dealmaking, declared on Tuesday that he'd just struck one of his best deals ever. "This is one of the biggest medical announcements that this office has ever made," Trump said in the Oval Office, flanked by his top health officials. They'd gathered to announce that the administration had cut a deal with the pharmaceutical giant Pfizer. Trump couldn't help but smirk. "I'm surprised you're agreeing to this," he told Albert Bourla, the CEO of Pfizer.